and the Bayer Cross was used as the trademark for all of the I.G.'s pharmaceutical products. In the early 1930s, the Wupperal-Elberfeld facility continued its successful research into drugs to ...

So I was intrigued to read last year about the radical plan to attack bureaucracy at German pharma company Bayer. The company ... and our products.” But little changes, he ventured, would ...

The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

Meanwhile, Bayer's Pharmaceutical division has delivered ... This growth was driven by significant gains from new products, with Nubeqa and Kerendia achieving growth rates of 83.2% and 96.4% ...

The optimism is rooted in new launches, Stefan Oelrich, head of Bayer’s pharma division, said Tuesday at the J.P. Morgan Healthcare Conference. Besides label expansions for in-market products ...

In a bold move to restore $540 million in cost savings, Bayer CEO Bill Anderson cut out ... teams with a clearer focused on our customers and products,” Hayes shares. Anderson’s push for ...

Bayer recently submitted an application to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for this third indication for darolutamide in addition ...

Bayer AG’s Monsanto unit stopped making toxic PCBs a half century ago, but the legal fallout lingers even as many of the ...

Bayer expects its pharmaceutical business to return to growth in 2027, unit President Stefan Oelrich said Monday. The German conglomerate is planning to launch new therapies — one that treats a ...

Bayer pharma chief sees no big acquisitions in near ... and potentially the rise of novel legal theories applied to less traditional products. Here are some of the top cases to watch in 2025.

( MENAFN - GlobeNewsWire - Nasdaq) Dublin, Jan. 20, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering.